文献类型：期刊文献

英文题名：Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease

作者：Xi, Meiyang[1,2];Sun, Tianyu[3];Chai, Shejie[4];Xie, Mengjiao[1];Chen, Siqi[1];Deng, Liping[1,2];Du, Kui[1,2];Shen, Runpu[1,2];Sun, Haopeng[3]

机构：[1]Shaoxing Univ, Coll Chem & Chem Engn, Shaoxing 312000, Peoples R China;[2]Shaoxing Univ, Zhejiang Engn Res Ctr Fat Soluble Vitamin, Shaoxing 312000, Peoples R China;[3]China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China;[4]Beida Pharmaceut Co Ltd, Hangzhou 310000, Peoples R China

年份：2022

卷号：232

外文期刊名：EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

收录：SCI-EXPANDED(收录号：WOS:000803062900005)、、Scopus(收录号：2-s2.0-85124229692)、WOS

基金：The authors greatly acknowledge the support from the Science Foundation of Shaoxing University (No. 2018LG1001).

语种：英文

外文关键词：AD; Cognition; PDE inhibitors; Selectivity

外文摘要：Alzheimer's disease (AD), one of the greatest threats to human health, is characterized by declined cognition and changed behavior. Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) that play an important role in learning and memory are hydrolyzed by phosphodiesterases (PDEs). Most PDE isoforms are highly expressed in the brain, and the inhibition of PDEs is beneficial to counteract AD. Thus, targeting PDEs represents a therapeutic potential for this disease. So far, a variety of PDE inhibitors have been discovered with significant cognitive enhancement effects in animal models and more than ten agents have entered into clinical trials. In this review, we summarize PDE mediated cyclic nucleotide signaling pathways, PDE family members involved in AD and recent advance of PDE inhibitors in preclinical and clinical studies, trying to provide an outlook of PDE inhibitors for the treatment of AD in future. (c) 2022 Elsevier Masson SAS. All rights reserved.